CME: human gastrointestinal system

Overview
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Sara Lonardi, MD
Chief, Oncology Unit 3
Veneto Institute of Oncology
Padova, Italy
Dr. Lonardihas reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Amgen, Astellas, AstraZenca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Hutchison, Incyte, Merati, Merck, SeronoConsulting Fees: Amgen, Astellas, AstraZenca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, GSK, Incyte, Lilly, Merck, Pieris, Serono
Aparna Parikh, MD
Associate Professor
Harvard Medical School
Boston, MA
Dr. Parikh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: BMS, Daiichi Sankyo, Erasca, Genentech, Mirati, Novartis, Parthenon, Plexxikon, PMV Pharmaceuticals, PureTech, Revolution Medicines, Syndax, Takeda
Ownership Interest: C2i Genomics, Cadex, Khora, Parithera, XGenomes
Consulting: AbbVie, Adroya, Amgen, AZ, Bayer, Biofidelity, Caris, Checkmate Pharmaceuticals, CVS, Delcath, Eli Lilly, Exact, Exelixis, FMI, Guardant, Hookipa, Illumina, Inivata, Kahar Medical, Merck, Mirati, MPM Capital, Pfizer, Roche, Saga, Scare Inc, Science For America, Seagen, Sirtex, Taiho, Takeda, Value Analytics Lab, Xilio Therapeutics
Alan Venook, MD
Madden Family Distinguished Professorship in
Medical Oncology and Translational Research
University of California San Francisco
San Francisco, CA
Dr. Venook has no relevant relationships reported.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Incorporate care that adheres to established guidelines for patients diagnosed with gastrointestinal malignancies
- Develop treatment plans informed by evidence and guidelines that encompass the full spectrum of gastric/GEJ, hepatocellular, and colorectal malignancies
- Analyze emerging data that may impact practice guidelines for patients diagnosed with gastrointestinal malignancies
- Implement treatment strategies tailored to specific regions, in accordance with NCCN Guidelines, for patients with gastrointestinal malignancies
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with gastrointestinal cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hour/0.1 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is JA0006235-0000-24-162-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credit(s). Approval is valid until 12/30/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc. and Bristol Myers Squibb.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/30/2024
Expiration Date: 12/30/2025